JBIO
Jade Biosciences, Inc.16.04
+0.79+5.18%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
737.91MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
8-K
$45M private placement priced
Jade Biosciences inked a private placement on December 13, 2025, selling 3,214,286 shares at $14.00 each to Biotech Growth N.V., expecting ~$45M gross proceeds before expenses. Closing set for December 16, subject to customary conditions. Funds will fuel R&D, corporate expenses, working capital. Biotech needs cash.
10-Q
Q3 FY2025 results
Jade Biosciences ramped R&D spend to $22.0M in Q3 ended September 30, 2025, up 62% y/y from $13.6M (derived), driving a $27.4M operating loss versus $15.0M last year—yet net loss narrowed to $25.2M from $16.3M on $2.3M interest income. JADE101 hit first-in-human dosing; Phase 1 advances alongside JADE201 tox studies and JADE-003 discovery, all via Paragon deals. Cash burned $61.0M YTD on $190.6M PIPE funding post-April reverse recap; $50.1M cash plus $148.8M investments fund runway. Reverse recap closed April 2025, converting $95.0M notes (12% rate, Dec 2026 maturity). Competition crowds IgAN space.
8-K
Q3 loss widens; $135M raised
Jade Biosciences reported Q3 2025 net loss of $25.2M, up from $16.3M YoY, as R&D expenses climbed to $22.0M from $13.6M amid Phase 1 JADE101 startup and JADE201 unveiling. Cash hit $198.9M, boosted by $135M private placement to ~$325.6M pro forma, funding ops into H1 2028. Pipeline advances. Strong runway secured.
8-K
Jade's $135M raise funds BAFF-R push
Jade Biosciences secured a $135 million private placement on October 6, 2025, issuing 13.4 million common shares at $9.14 each and pre-funded warrants for 1.4 million shares, closing October 8 to fund R&D into H1 2028. Yet the real kicker: a BAFF-R license from Paragon on October 3 grants exclusive rights to JADE201, an afucosylated antibody for deeper B-cell depletion in autoimmune diseases. First-in-human RA trial starts H1 2026. Cash bolsters pipeline risks.
8-K
CMO departs with severance
Jade Biosciences' Chief Medical Officer, Hetal Kocinsky, M.D., departed effective September 9, 2025, with the company planning a separation agreement offering 12 months' base salary and COBRA premium coverage. Scientific and clinical programs proceed under Dr. Andrew King, Ph.D., as Chief Scientific Officer. Leadership continuity holds firm. The pending agreement details remain undisclosed.
CLYM
Climb Bio, Inc.
4.62+0.81
FBLG
FibroBiologics, Inc.
0.24-0.02
IMA
ImageneBio, Inc.
6.25+0.08
JSPR
Jasper Therapeutics, Inc.
1.71+0.07
PALI
Palisade Bio, Inc.
1.72-0.09
QTTB
Q32 Bio Inc.
2.88-0.17
THAR
Tharimmune, Inc.
2.41+0.01
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZURA
Zura Bio Limited
4.12+0.05